Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Key PointsViking is testing weight loss drug candidates in late-stage trials.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.